Zobrazeno 1 - 10
of 164
pro vyhledávání: '"T. Fine"'
Autor:
Srihari S. Naidu, Megan B. Sutton, Wei Gao, Jennifer T. Fine, Jipan Xie, Nihar R. Desai, Anjali T. Owens
Publikováno v:
Journal of Medical Economics. 26:682-690
The diagnostic history in the years leading up to the definitive diagnosis of patients with obstructive hypertrophic cardiomyopathy (HCM) has not been studied. Patients with a delay in the definitive diagnosis of obstructive HCM from January 2009 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ff7de5a74662e1e8fef72f3700207e
https://doi.org/10.1080/13696998.2023.2208966
https://doi.org/10.1080/13696998.2023.2208966
Autor:
Nihar R. Desai, Megan B. Sutton, Jipan Xie, Jennifer T. Fine, Wei Gao, Anjali T. Owens, Srihari S. Naidu
Publikováno v:
The American Journal of Cardiology. 192:16-23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8e66aaebe2a9f7ef2aa37ea466df503
https://doi.org/10.1016/j.amjcard.2022.12.030
https://doi.org/10.1016/j.amjcard.2022.12.030
Autor:
Anjali T. Owens, Megan B. Sutton, Wei Gao, Jennifer T. Fine, Jipan Xie, Srihari S. Naidu, Nihar R. Desai
Publikováno v:
Cardiology and Therapy. 11:249-267
There is limited evidence on therapies for obstructive hypertrophic cardiomyopathy (HCM), and data regarding treatment patterns and cost are scarce. This study assessed treatment patterns and economic outcomes in patients with symptomatic obstructive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fe0973f54e9cf7428867c62aaee40c
https://doi.org/10.1007/s40119-022-00257-7
https://doi.org/10.1007/s40119-022-00257-7
Autor:
David J. Cohen, John A. Spertus, Jay M. Edelberg, Jennifer T. Fine, Megan B. Sutton, Wei Gao, Sneha S. Jain, Sophia S. Li, Jipan Xie
Publikováno v:
Journal of Medical Economics. 24:1115-1123
Obstructive hypertrophic cardiomyopathy (oHCM) is a disease of the cardiomyocyte in which dynamic left ventricular outflow track obstruction may lead to heart failure, valvular disease, and sudden death. Little is known about healthcare resource util
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ebee0cccbc177cf363c21e35cabcb59
https://doi.org/10.1080/13696998.2021.1978242
https://doi.org/10.1080/13696998.2021.1978242
Autor:
Matthew Reaney, Prithvi Addepalli, Veleka Allen, John A. Spertus, Chantal Dolan, Amy J. Sehnert, Jennifer T. Fine
Publikováno v:
PharmacoEconomics - open. 6(4)
Hypertrophic cardiomyopathy (HCM) symptoms include shortness of breath (SOB), fatigue, chest pain, palpitations, dizziness, and fainting. The HCM Symptom Questionnaire (HCMSQ), the only patient-reported outcome instrument designed to specifically mea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31cb9677de06589f6de7fd201c7014f1
https://pubmed.ncbi.nlm.nih.gov/35718845
https://pubmed.ncbi.nlm.nih.gov/35718845
Autor:
Jory Denny, Benjamin T. Fine
Publikováno v:
IEEE Robotics & Automation Magazine. 26:102-110
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c272dd3e5840deb517d87ebfc52fed28
https://doi.org/10.1109/mra.2019.2891182
https://doi.org/10.1109/mra.2019.2891182
Autor:
Carolyn Y. Ho, Amy J. Sehnert, Jennifer T. Fine, Matthew Reaney, Perry M. Elliott, Chantal M. Dolan, Daniel Jacoby, John A. Spertus, Wanying Li, Sara Saberi, Iacopo Olivotto
Publikováno v:
Lancet (London, England). 397(10293)
Improving symptoms is a primary treatment goal in patients with obstructive hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic cardiomyopathy are not disease-specific and are often inadequate or poorly tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c82a806e841a6500ce17fd02e3a135b6
https://pubmed.ncbi.nlm.nih.gov/34004178
https://pubmed.ncbi.nlm.nih.gov/34004178
Autor:
Jory Denny, Benjamin T. Fine
Publikováno v:
SAC
Multi-agent routing is an important aspect to studying livestock management, traffic patterns, and pedestrian egress. However, much of the literature does not fully account for the underlying dynamics of the agents' group level behavior or fluctuatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3070b1d5f0fb117a6dcb8539acf1e1b7
https://doi.org/10.1145/3341105.3373965
https://doi.org/10.1145/3341105.3373965
Autor:
Nihar Desai, Jipan Xie, Yan Wang, Megan B. Sutton, John Whang, Jennifer T. Fine, Louis P. Garrison
Publikováno v:
Clinical Therapeutics. 44:52-66.e2
The aim of the study was to project the long-term net health benefits of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the United States.A Markov model with 4 mutually exclusive health states (New York H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e41778d1e0a265baa4198a76b5d165
https://doi.org/10.1016/j.clinthera.2021.11.006
https://doi.org/10.1016/j.clinthera.2021.11.006
MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists
Publikováno v:
Drug Safety
Introduction Within the field of Pharmacovigilance, the most common approaches for assessing causality between a report of a drug and a corresponding adverse event are clinical judgment, probabilistic methods and algorithms. Although multiple methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a04be19fd7eb7424c4f9552e780097
https://doi.org/10.1007/s40264-018-0690-y
https://doi.org/10.1007/s40264-018-0690-y